Introduction
Gastric cancer is the second most common cause of cancer-associated death and fourth most commonly diagnosed cancer worldwide (1) . Annually, 0.7 million patients with gastric cancer die globally (2) . The cancer is associated with glycosylation changes, but how alteration of gastric mucins relates to gastric cancer pathogenesis remains unknown. Despite the protection by mucins and the acidic gastric juice and proteolytic enzymes, the bacterium Helicobacter pylori manage to thrive in the gastric lining, infecting about half of the world's population (3) .
There is a direct correlation between infection and gastric cancer, where 0.1-3% of infected individuals develop gastric adenocarcinoma or mucosa-associated lymphoid tissue lymphoma and another 10-15% develop symptomatic gastritis or gastric and duodenal ulcers, whereas the majority show no symptoms (4).
In the stomach, MUC5AC and MUC6 are the major secreted mucins, while MUC1 is the dominant membrane-associated mucin. MUC5AC is produced by the surface epithelium, whereas MUC6 is secreted from the deep glands of the gastric mucosa (5, 6) . Both MUC5AC and MUC6 are large oligomeric mucins that occur as distinct glycoforms (7) . In gastric precancerous lesions and cancer, altered expression of MUC5AC, MUC6, MUC2 and MUC5B has been described, with MUC2 being a marker for intestinal metaplasia (8, 9) . The gastric surface and foveolar epithelium are formed by a single layer of tall columnar mucin-producing cells that have a basal nucleus below an apical cup of mucin. These cells have a turnover rate of 3-6 days, but the mucus layer produced in these cells have an even shorter life span: the production rate from start of glycosylation until release at the apical side is about 6 hours (10), demonstrating that both the mucin repertoire and glycosylation theoretically can change rapidly. The carbohydrate structures present on mucosal surfaces vary according to cell lineage, tissue location, and developmental stage (11) . The massive O-glycosylation of the mucins protects them from proteolytic enzymes and induces a relatively extended conformation.
The dominating type of carbohydrate chains on mucins consist of extended oligosaccharides initiated with N-acetylgalactosamine (GalNAc) linked to a hydroxyl group on serine or threonine, elongated by the formation of the so-called core structures (core [1] [2] [3] [4] [5] [6] [7] [8] , and followed by the backbone region (type 1 or 2 chain). The chains are terminated by e.g. fucose (Fuc), galactose (Gal of type 1 or 2 chain), GalNAc or sialic acid (Neu5Ac) residues in the peripheral region, are expressed in mucous, chief and parietal cells of the glands (12) . Thus, the Le type-1 structures co-localize with MUC5AC whereas Le type-2 structures co-localize with MUC6 (12) , although this distribution is not always distinct (12) (13) (14) . The carbohydrate structures present depend on the glycosyltransferases expressed in the cells, i.e. by the genotype of the individual.
The terminal structures of mucin oligosaccharides are heterogeneous and vary between/within species and even with tissue location within a single individual (12, 15) . Possibly, this structural diversity allows us to cope with diverse and rapidly changing pathogens, as reflected by the observation that susceptibility to specific pathogens differs between people with different histo-blood groups (16) . Mucins appear to be the major carrier of aberrant glycosylation in carcinomas, and incomplete glycosylation, leading to expression of Tn and T antigens, and/or sialylation/sulfation is common (15, 17) . The sLe x and sLe a are frequently overexpressed in carcinomas, and expression of these antigens by epithelial carcinomas correlates with tumor progression, metastatic spread and poor prognosis (17) .
Mucins from different individuals differ in their effect on H. pylori growth, adhesion and expression of virulence genes (18) (19) (20) , and the Le b and 1,4GlcNAc are two structural epitopes that have been shown to participate in regulation of H. pylori growth (21, 22 
Experimental procedures

Isolation of mucins
Gastric specimens were obtained after informed consent and approval of local ethics committees (Lund University Hospital, Lund, Sweden). Mucins were isolated from frozen gastric specimens as described previously (19) . In brief, four of the specimens (P1T, P2T, P3T and P4T)
were from gastric adenocarcinoma tumors (intestinal type) and another three (P5TA, P6TA and P7TA) were from macroscopically normal mucosa of tumor-adjacent stomachs ( Table 1) . Two of the tumors contained both soluble (S) and insoluble mucins (I, e.g. P1TS and P1TI, in which the insoluble MUC2 mucin was later solubilized by reduction and alkylation) whereas the insoluble fractions from the other tumors did not contain MUC2, MUC5B, MUC6 or MUC5AC (i.e. were considered negative for mucins). The specimens (approximately 1.5x1.5 cm) of normal mucosa isolated from tissues adjacent to gastric tumors (tumor-adjacent, TA) were separated into fundus (F) versus pyloric antrum (A), surface (S) versus gland material (G) according to tissue location, e.g. P5TA-AS and P6TA-FG. In addition, three specimens (P8H, P9H, and P10H) were from the junction between antrum and corpus of patients who underwent elective surgery for morbid obesity. Mucins were isolated by isopycnic density gradient centrifugation from these materials as previously described (23) . Gradient fractions containing mucins were pooled together to obtain one sample for each gradient. , and 1,4-GlcNAc, were evaluated in previous study (19) .
In situ proximity ligation assay (PLA)
In situ proximity ligation assay (PLA) was performed with paraffin-embedded sections from human gastric tissues for the detection of proximity of blood group antigens (ABH) and MUC5AC. These samples were obtained after written informed consent (Ersta Diaktioni, Sweden) in conjunction with obesity surgery and they had a normal histology. MUC5AC (polyclonal rabbit anti-oligomeric mucus/gel-forming MUC5Ac N-term aa552-567, at a concentration of 5 g/ml, antibodies-online GmbH, Aachen, Germany) were used and incubated at 4C overnight. Antibodies conjugated with oligonucleotides were utilized to examine the proximity for 1 hour at 37C (Olink Bioscience). Ligation and amplification were performed at 37C for 30 min and 90 min, respectively. The cell nuclei were visualized by DAPI.
Sections were examined under a Zeiss Imager Z1 Axio fluorescence microscope (Zeiss, Welwyn
Garden City, UK). The proximity ligation resulted in bright red fluorescent dots. Images were acquired using a Zeiss Axio cam MRm and the AxioVision Rel 4.8 software.
Release of O-linked oligosaccharides for LC-MS
Isolated mucins were dot-blotted onto PVDF membranes (Immobillin P, Millipore), stained with direct blue 71 (Sigma-Adrich) and destained with a solution of 10% acetic acid in 40% ethanol.
The O-glycans were released from PVDF membranes as described previously (24) . V and capillary temperature of 300°C. Air was used as a sheath gas and mass ranges were defined depending on the specific structure to be analyzed. The data were processed using Xcalibur software (version 2.0.7, Thermo Scientific). Glycans were annotated from their MS/MS spectra manually and validated by available structures stored in UniCarb-DB database (2015-12 version) (25) . The annotated structures were submitted to the UniCarb-DB database and they will be included in the next release.
For structural annotation, some assumptions were used in this study: monosaccharides in the reducing end were assumed as GalNAcol; GalNAc was used for HexNAc when identified in blood group A and LacdiNAc sequences, otherwise HexNAc was assumed to be GlcNAc; hexose was interpreted as Gal residues. The presence of core 1-4 has been reported in gastric tissue (15, 26, 27) . In this study, reducing end with sequence of Hex-HexNAcol and retention time (RT) shorter than 8 min on PGC column was assumed be to core 1 disaccharide, Hex-(HexNAc-)HexNAcol as core 2 trisaccharide, HexNAc-HexNAcol as core 3 and 5 disaccharides with core 3 having shorter RT on PGC column (28) , and HexNAc-(HexNAc-)HexNAcol as core 4 trisaccharide. The discovery of core 5 structures (isomeric to core 3) were assumed to be only present as di-and trisaccharides, and they were validated with RT compared to standards obtained from our previous studies (29, 30 (24, 28, 31) .
Elongation was assumed to occur as N-acetyl-lactosamine units (Hex-HexNAc or Galβ1-4GlcNAcβ1-3). Terminal epitopes corresponding to blood group ABH, Lewis a/x, Lewis b/y and LacdiNAc were assumed based on the sequences detected in their MS/MS spectra (24, 28, 31) .
Terminal HexNAc was assumed to be GlcNAc, since distal β1,3GlcNAc residues were usually capped with Gal residues as result of highly active galactosyltransferases. Validation of smaller structures (<7 residues) was made by RT comparison with standards (29, 30) and/or MS/MS spectral matching using Unicarb-DB database (25) . Larger structures were identified by de-novo sequencing of MS/MS spectra, epitope specific fragmentation and biosynthetic pathways (core type and blood group ABH).
Proposed structures are depicted using the Symbol Nomenclature for Glycomics (SNFG) (32) and nomenclature of fragments of carbohydrates as defined by Domon and Costello (33) .
Data analysis
To identify the most closely related structural features (epitopes), we generated clustered given in percentage (%) of the total sum of integrated peak areas in the LC-MS chromatograms (Supplementary table) . Due to high variability between samples, the rows were not clustered and we kept the order according to the subject groups (gastric adenocarcinoma, adjacent normal mucosa, and normal). The Manhattan distance algorithm was selected for distance measurements and average linkage was selected for clustering, which defined the distance as the average of all pairs from each cluster group. Color-coded CIM that determines the distance and linkage between clustered columns (calculated glycan structural features) is represented in Figure 8D .
Statistical analysis was performed using the GraphPad Prism 6.0 software package (GraphPad Software Inc., San Diego, CA). Results were expressed as mean±SD. The statistical differences were calculated by the two-tailed Student's t-test.
Results
The purpose of this study was to address the heterogeneity of mucin glycans present in the stomach. One question is if the blood group and secretor status of a patient (expressed on for instance MUC5AC, Figure 1 ) are the main factors contributing to the inter-individual variation of the gastric mucin glycans. Alternatively, there could be other differences that dominate differentiation of inter-and intra-individual mucin subpopulations. In order to address this, mucins from three types of tissues were included in this study: normal (P8H, P9H, and P10H), normal mucosa of tumor-adjacent tissue (P5TA, P6TA, and P7TA) and gastric adenocarcinoma tumor (P1T, P2T, P3T and P4T, Table 1 ). In total, 17 mucin samples were obtained from these 10 individuals according to the solubility (soluble/insoluble) and location (surface/gland) ( Table 1 ).
The presence of mucins (MUC5AC, MUC6, MUC2 and MUC5B), Lewis antigen (Le b and sialyl Le a/x ) and α1,4-GlcNAc were evaluated by ELISA in our previous study (19) . After reductive β-elimination, at least 258 O-glycans were identified by LC-MS/MS using on-line graphitized carbon column in negative-ion mode (Supplementary Table) . As an overview, we found that human gastric O-glycans in most samples were dominated by neutral and fucosylated structures in all three tissue types (normal, tumor adjacent and tumor), although gastric Oglycans from cancerous tissue contained higher level of sialylation and sulfation than healthy tissue. The diversity of O-glycans were also reflecting the presence of blood type ABH epitopes and i/I-branches, as well as terminal α1,4-GlcNAc-like and GalNAcβ1-4GlcNAc (LacdiNAc)-like structures.
Core types of human gastric O-glycans
In the analyzed samples, structures with monosaccharide sequences corresponding to core 2 Oglycans were found to be the dominating core of the gastric O-glycans, followed by sequences interpreted as core 1, 3/4 and 5 ( Figure 2 , Table 1 and Supplementary table) . Figure 2B ; m/z 1081, 4 A 0α in Figure 4C ) and typical 0,2 A GlcNAc / 0,2 A GlcNAc - indicated that Neu5Ac was linked to C6 of which was assumed to be a reducing end GalNAc alditol residue. Based on our previous study (28) , the structure with short retention time (RT at 14.18 min) was assigned as sialylated core 3 like structure; while the one with longer RT at 17.03 min was assigned as sialylated core 5 ( Figure 2D ). The remaining 11 gastric O-glycans were most likely derived from extension of core 3 O-glycans although the possibility that they were also core 5 O-glycans cannot be ruled out.
Interpretation of i/I-branch like structures on human gastric O-glycan
Analysis of complex extensions of human gastric O-glycans showed that 36 out of 258 (14% of the detected structures) carried what was interpreted as I-branches, Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ-. These were found to be attached to the C3 branches of core 2 like or extended core 1 like O-glycans ( Figure 3A and Supplementary Table) . These branches were further modified by ABH and/or Lewis blood group like antigens as well as sialylation and/or sulfation.
I-branched like O-glycans could also be distinguished from their linear i-like isomers in MS/MS spectra. As shown in Figure 3A , the fragmentation ions at m/z 975 suggested consecutive loss of three Hex residues from the parent ions. The discontinuous B-ions (B-ions at m/z 364 and 891) suggested that those ions were derived from a branched structure rather than a linear one.
In addition, only cross-ring fragment ions from terminal LacNAc were observed (e.g., A-ions at m/z 221, 263, 281 and 424 in Figure 3A ) indicative of single LacNAc (branched) rather than linear oligo-LacNAc. Taken together, the annotated structure contained three terminal LacNAc like sequences with two of them forming the I-branch on the C3 branch of a core 2 like O-glycan.
Combining with other I-branch like containing O-glycans, the typical MS/MS spectra of I-branch
containing O-glycans usually contained B-ions with the intact I-branch (e.g., B 3α ions at m/z 891 in Figure 3A ), A-ions from both C6 and C3 branch, and a lack of the continuous A-and B-ions present in the structures containing extended oligo-LacNAc like structures (e.g., B 2 , B 3 and B 4 ions at m/z 364, 567, and 729 in Figure 3B ).
Blood group like antigens on human gastric O-glycans
In Figure 5C ). Up to four fucose residues were found in one structure (1698 in Supplementary table), which have both Le a/x and Le b/y like epitopes.
LacdiNAc-like and 1,4-GlcNAc-like epitopes on human gastric O-glycan
Among 258 O-glycans, 44 O-glycans (17% of the detected structures and 9.3±8.3% of the intensity) were assumed to be 1,4-GlcNAc-like structures, since distal β1,3GlcNAc residues were usually capped with Gal residues as result of highly active galactosyltransferases. Some of these structures were previously identified in porcine stomach (36, 37) . Most of the 1,4-GlcNAc-like structures in human tissue (91%) where found on core 2 like O-glycans ( Figure 6 and Supplementary table) 
Diversity of O-glycans in health and diseased gastric tissues
The diversity of human gastric O-glycans reflected by chromatographic profiles was due to not only different peak numbers but also varied abundance of same peak in different samples (e.g., Figure 8A -C). In order to display the great variety of human gastric O-glycans a clustered image map with various glyco-epitopes was made ( Figure 8D ). The clustered groups revealed that the majority of structures was fucosylated core 2 O-glycans in human gastric mucins ( Figure 8D ).
Indeed, the major fucosylation was attributed to the prevalence of blood type H like epitopes (Fucα1-2Galβ-), indicating that blood group and secretor status were the main contributing factor for gastric blood group variation. Furthermore, despite that most sialylated structures detected were based on core 2 like structures, the sialylated core 1 like O-glycans, due to their less diversity, (675-1, 675-2 and 966 in Supplementary table) had a higher relative abundance.
Thus, sialylation was clustered with core 1 like O-glycans in the map ( Figure 8D ). The sialyl Tn and sulfated glycans were often found in tumor tissue, though not exclusively ( Table 1 ). However, these differences were not significant (0.14>p>0.09) and larger cohorts would be needed to investigate this. Interestingly, our data corroborates previous findings (39, 40) indicating that in addition to the stomach being a region of high diversity in humans, the diversity in human glycosylation may be higher than for other species.
Several studies have implied that gastric O-glycans containing 1,4-GlcNAc inhibit H. pylori colonization and growth (21, 45, 46) . And it is well known that H. pylori is a causative microbe for gastric cancer (47) . In the present study, we detected high levels of 1,4-GlcNAc-like structures (9.3±8.0%, Table 1 ) in all tested samples except one. Thus, with our sample preparation, α1,4-GlcNAc was not a unique modification of mucins (such as MUC6) secreted from gastric gland mucous cells and Brunner's glands of the duodenal mucosa (39) . The average level was higher than in another study where the level of expressed 1,4-GlcNAc was around 2.0±0.6% in 32 healthy individuals (48) . The highest level was associated with mucins secreted from gland mucous cells of pyloric antrum and fundus (20.0±8.2%, Table 1 ). Higher prevalence of 1,4-GlcNAc-like structures in mucins from glands, where MUC6 dominate, is in agreement with that glands has been shown to be responsible for its secretion (39, 40) , and also with ELISA based results from the patients present in this study (19) . Terminal 1,4-GlcNAc has also been indicated as a tumor suppressor for gastric adenocarcinoma in the study of A4GNT-deficient mice (49) . However, the level of 1,4-GlcNAc in tumor tissue was similar to that from normal control (8.4 versus 5.2%, Table 1 ). However, it should be noted that the relative rather than absolute amount of selected glycans was used for comparison in this report. In our previous ELISA based study of these samples, the mucins from full gastric wall mucosa from tumor and healthy samples either had a low or no detectable level of 1,4-GlcNAc, whereas this structure was enriched in the mucins samples isolated from the glands only (19) . Another study based on immunohistochemistry, also report tumor tissue to usually be negative for terminal α1,4-GlcNAc (40) . The apparent discrepancy between the current study and these previous studies may be in that ELISA and immunohistochemistry usually are optimized to an antibody concentration where the highest signal of the sample set is set so it is in the linear range of the method, which may lead to those samples with low abundance fall below the detection limit.
The LacdiNAc-binding adhesin (LabA) from H. pylori binds to the LacdiNAc motif on MUC5AC (41) . The expression of LacdiNAc was absent in cardiac gland, low in the surface of the fundic mucosa but more pronounced in pyloric glands (41) . In this study, the O-glycans with LacdiNAclike epitopes represented around 4% in normal tissue and tended to be lower in tumor and tumor-adjacent tissue. The value in normal tissue was similar to that of other studies where 3.4-7.0% relative abundance was reported, although a higher abundance has been found in intestinal metaplasia (8.5%) (41, 50) . Sulfated LacdiNAc-like structure with sulfate linked to C6
of GlcNAc was different from reported sulfated LacdiNAc so far, where sulfate was linked to C4 position of GalNAc on both N-and O-glycans of human glycoprotein hormones as well as other glycoproteins (51, 52) . This indicates that gastric LacdiNAc undergoes a different modification in comparison with that of brain and trachea (51, 52) .
There was a trend that cancerous tissue tends to have higher level of sulfation and sialylation in this study. This is in agreement with the appearance of sulfomucins associated with the metaplastic process advances (50, 53) In conclusion, the gastric mucin O-glycosylation has a greater diversity than previously appreciated, and we identified some novel structures and linkages not described for this type of samples before. The diversity the gastric O-glycosylation broaden our understanding of the human gastric O-glycome and the structures presented in this study can function as a library for candidate structures important for pathogenesis, to be tested in biological assays. Tables   Table 1. Distribution of O-glycan features on mucins from gastric adenocarcinoma tumor (Tumor), normal mucosa of tumoradjacet tissue (Norm.tum.adj) and normal tissue (Normal). The relative amounts of the different glycan features are given in percentage (%) in the relation to the total sum of integrated peak areas in the LC-MS chromatograms. 
